Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019882 | 0.84 | GAA (0.70) | GAASMN1; SMN2DRD4HTTLMNA | |
| SCHEMBL11120307 | 0.84 | GAA (0.70) | GAASMN1; SMN2DRD4HTTLMNA | |
| SCHEMBL12126914 | 0.79 | GAA (0.58) | GAASMN1; SMN2CHRNA7HTTLMNA | |
| SCHEMBL9565835 | 0.79 | KDM4E (0.66) | DRD4CHRNA7LMNAALDH1A1DRD2 | |
| SCHEMBL8138271 | 0.79 | DRD4 (0.62) | GAADRD4LMNAMAPTALDH1A1 | |
| SCHEMBL1308333 | 0.79 | ADRA2C (0.60) | GAASMN1; SMN2DRD4HTTLMNA | |
| SCHEMBL17764863 | 0.78 | ADRA2C (0.65) | GAASMN1; SMN2CHRNA7LMNAMAPT | |
| SCHEMBL8044642 | 0.78 | KDM4E (0.65) | GAASMN1; SMN2DRD4CHRNA7ALDH1A1 | |
| SCHEMBL8375058 | 0.77 | ADRA1B (0.59) | GAADRD4HTTHTR7DRD2 | |
| SCHEMBL11096500 | 0.76 | CHRNA7 (0.59) | SMN1; SMN2DRD4CHRNA7DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011566-A1 | N-PHENYLPIPERAZINE DERIVATIVES THAT ARE ANTAGONISTS OF A1A, A1D ADRENOCEPTORS AND 5-HT1A RECEPTORS FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UNIAO BRASILIENSE DE EDUCACAO E CULTURA - UBEC (BR) | 2015-01-08 | — | — | US | disclosed |
| US-20150011566-A1 | N-PHENYLPIPERAZINE DERIVATIVES THAT ARE ANTAGONISTS OF A1A, A1D ADRENOCEPTORS AND 5-HT1A RECEPTORS FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UNIAO BRASILIENSE DE EDUCACAO E CULTURA - UBEC (BR) | 2015-01-08 | — | — | US | disclosed |
| EP-2810938-A1 | N-PHENYLPIPERAZINE DERIVATIVES THAT ARE ANTAGONISTS OF A1A, A1D ADRENOCEPTORS AND 5-HT1A RECEPTORS FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Universidade Federal Do Rio De Janeiro - UFRJ (BR) | 2014-12-10 | — | — | EP | disclosed |
| US-20070218002-A1 | Method for Detecting Alzheimer's Disease and other Forms of Dementia, and Measuring Their Progression | ENERGY, UNITED STATES DEPARTMENT OF | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011566-A1 | N-PHENYLPIPERAZINE DERIVATIVES THAT ARE ANTAGONISTS OF A1A, A1D ADRENOCEPTORS AND 5-HT1A RECEPTORS FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADRA1D, ADRA1A, ADRA1B | GAA 4130/4885SMN1; SMN2 3574/4885DRD4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.